Dr Barry Hardy

Dr Barry Hardy

Job Title: 
Managing Director (CEO)

 

Dr Barry Hardy is leading Edelweiss Connect and its team supporting the development of new integrating solutions in industrial safety assessment. An example application is that for integrated testing for skin sensitization available at https://its.douglasconnect.com/

He has coordinated the OpenTox project in predictive toxicology and the ToxBank infrastructure development project. He is currently President of the OpenTox Association, founded in 2015 as an international non-profit organisation promoting an open knowledge community approach to new methods in predictive toxicology.

He recently led the infrastructure development for the IMI EBiSC stem cell banking project and the eNanoMapper project developing OpenTox solutions supporting nanotechnology safety assessment. New projects include leading OpenRiskNet, knowledge infrastructure development for ACEnano and Eu-ToxRisk and translation of research methods to industrial practice within ToxHQ.

He has led the development of research and best practice activities in drug design and toxicology through founding the eCheminfo Community of Practice, InnovationWell and leading the Scientists Against Malaria project.

Dr. Hardy obtained his Ph.D. in 1990 from Syracuse University working in computational science. He was a National Research Fellow at the FDA Center for Biologics and Evaluation, a Hitchings-Elion Fellow at Oxford University and CEO of Virtual Environments International. 

He was a pioneer in the 1990s in the development of Web technology applied to virtual scientific communities and conferences. He has developed technology solutions for internet-based communications, tutor-supported e-learning, laboratory automation systems, and computational science and informatics.

In recent years he has also been active in the field of knowledge management as applied to supporting innovation, communities of practice, and collaboration.

Latest Tweets

Edelweiss Connect (3 hours ago)
Learn more about our recently launched application at #Chemspec Europe 2019. SaferSkin uses an ITS approach to prov… https://t.co/AVDsDMgrVE
Edelweiss Connect (3 hours ago)
We are excited to be at @ChemspecEurope this week! Stop by Stand B316 to speak with the Edelweiss team. #basel… https://t.co/qFlOlHTOfO
Edelweiss Connect (3 hours ago)
RT @openrisknet: Did you miss the live webinar yesterday on the Deploying Applications to an OpenRiskNet Virtual Environment https://t.co/w…
Edelweiss Connect (2 weeks ago)
RT @LucianFarcal: Discover our @EUNanoSafety stand activities at @ENF_2019 in Bucharest, 12-14 June: https://t.co/sVFWSdmEqo Learn more abo…
Edelweiss Connect (2 weeks ago)
Some benefits of SaferSkin™ = No #animaltesting required, saves you time, increases your accuracy, decreases the ri… https://t.co/5Xbo780fRR

Get in touch

  • Address: Edelweiss Connect GmbH
    Technology Park Basel
    Hochbergerstrasse 60C
    CH-4057 Basel / Basel-Stadt
    Switzerland
  • Phone: +41 61 633 29 78
  • Email: info@edelweissconnect.com

USA office

  • Address: Edelweiss Connect Inc
    Research Triangle Park NC
    800 Park Offices Dr
    Durham, NC 27709
    USA
  • Phone: +1 252 654 9003
  • Email: info@edelweissconnect.com